Amryt Pharma plc Director/Pdmr Shareholding
08 Março 2021 - 3:00PM
UK Regulatory
TIDMAMYT
Grant of Options and Notification of Transactions by Persons Discharging
Managerial Responsibilities
DUBLIN, Ireland, and Boston MA, March 8, 2021, Amryt (Nasdaq: AMYT, AIM:
AMYT), a global, commercial-stage biopharmaceutical company focussed on
acquiring, developing and commercializing novel treatments for rare
diseases, today announces that the Remuneration Committee has approved
the grant of 3,431,350 share options ("Options") to subscribe for
ordinary shares in the Company ("Shares") under the Employee Share
Option Plan 2019 (the "Plan") to Joe Wiley, CEO, and Rory Nealon, CFO,
details of which are set out in the table below.
The Options have an exercise price of US$2.804 per Share ($14.02 per ADS
equivalent) ("Exercise Price"). These options may be exercised as
follows:
-- 25% of the total Options granted may be exercised 12 months
after the date of grant;
-- a further 25% of the total Options granted may be exercised
24 months after the date of grant; and
-- the balance of the Options may be exercised 36 months after
the date of grant.
All Options are subject to change of control provisions and expire on
the seventh anniversary of their grant.
Following the grants of these options, the following Director and
Company Secretary have the following options:
Director / Company Secretary Options granted Total Options now held
----------------------------- --------------- ----------------------
Joe Wiley 2,031,350 8,468,810
----------------------------- --------------- ----------------------
Rory Nealon 1,400,000 6,226,823
----------------------------- --------------- ----------------------
PDMR Dealings
The notification of dealing forms for each Director/Company Secretary
can be found below. This announcement is made in accordance with
Article 19 of the EU Market Abuse Regulation 596/2014.
Details of the person discharging managerial responsibilities
1. / person closely associated
--- -----------------------------------------------------------------------
a) Name Joe Wiley
--- ------------------------ ---------------------------------------------
2. Reason for the notification
--- -----------------------------------------------------------------------
a) Position / status Director
--- ------------------------ ---------------------------------------------
Initial notification
b) / amendment Initial notification
--- ------------------------ ---------------------------------------------
Details of the issuer, emission allowance market participant,
3. auction platform, auctioneer or auction monitor
--- -----------------------------------------------------------------------
a) Name Amryt Pharma plc
--- ------------------------ ---------------------------------------------
b) Legal entity identifier 213800YNUJEOJ84L4T95
--- ------------------------ ---------------------------------------------
Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
4. where transactions have been conducted
--- -----------------------------------------------------------------------
Description of the
financial instrument,
a) type of instrument Ordinary shares of GBP0.06 each
Identification code ISIN: GB00BKLTQ412
--- ------------------------ ---------------------------------------------
Grant of options under the Employee
Share Option Plan 2019 with an
Nature of the exercise price of US$2.804 to purchase
b) transaction 2,031,350 ordinary shares.
--- ------------------------ ---------------------------------------------
c) Currency US Dollar
--- ------------------------ ---------------------------------------------
d) Price(s) and volume(s) Price(s) Volume(s)
--- ------------------------ ------------------- ---------------------
N/A 2,031,350
------------------------------------------------ ---------------------
e) Aggregated information
Aggregated volume 2,031,350
Aggregated price N/A
--- ------------------------ ---------------------------------------------
f) Date of the transaction 8 March 2021
--- ------------------------ ---------------------------------------------
g) Place of the transaction Outside a trading venue
--- ------------------------ ---------------------------------------------
Details of the person discharging managerial responsibilities
1. / person closely associated
--- -----------------------------------------------------------------------
a) Name Rory Nealon
--- ----------------------- ----------------------------------------------
2. Reason for the notification
--- -----------------------------------------------------------------------
a) Position / status PDMR -- CFO and Company Secretary
--- ----------------------- ----------------------------------------------
Initial notification
b) / amendment Initial notification
--- ----------------------- ----------------------------------------------
Details of the issuer, emission allowance market participant,
3. auction platform, auctioneer or auction monitor
--- -----------------------------------------------------------------------
a) Name Amryt Pharma plc
--- ----------------------- ----------------------------------------------
b) Legal entity identifier 213800YNUJEOJ84L4T95
--- ----------------------- ----------------------------------------------
Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place where
4. transactions have been conducted
--- -----------------------------------------------------------------------
Description of the
financial instrument,
a) type of instrument Ordinary shares of GBP0.06 each
Identification code ISIN: GB00BKLTQ412
--- ----------------------- ----------------------------------------------
Grant of options under the Employee
Share Option Plan 2019 with an exercise
Nature of the price of US$2.804 to purchase 1,400,000
b) transaction ordinary shares.
--- ----------------------- ----------------------------------------------
c) Currency US Dollar
--- ----------------------- ----------------------------------------------
d) Price(s) and volume(s) Price(s) Volume(s)
--- ----------------------- -------------------- ---------------------
N/A 1,400,000
------------------------------------------------ ---------------------
e) Aggregated information
Aggregated volume 1,400,000
Aggregated price N/A
--- ----------------------- ----------------------------------------------
f) Date of the transaction 8 March 2021
--- ----------------------- ----------------------------------------------
g) Place of the Outside a trading venue
transaction
--- ----------------------- ----------------------------------------------
About Amryt
Amryt is a global commercial-stage biopharmaceutical company focused on
acquiring, developing and commercializing innovative treatments to help
improve the lives of patients with rare and orphan diseases. Amryt
comprises a strong and growing portfolio of commercial and development
assets.
Amryt's commercial business comprises two orphan disease products --
metreleptin (Myalept(R)/ Myalepta(R)) and lomitapide (Juxtapid(R)/
Lojuxta(R)).
Myalept(R) / Myalepta(R) (metreleptin) is approved in the US (under the
trade name Myalept(R)) as an adjunct to diet as replacement therapy to
treat the complications of leptin deficiency in patients with congenital
or acquired generalized lipodystrophy (GL) and in the EU (under the
trade name Myalepta(R)) as an adjunct to diet for the treatment of
leptin deficiency in patients with congenital or acquired GL in adults
and children two years of age and above and familial or acquired partial
lipodystrophy (PL) in adults and children 12 years of age and above for
whom standard treatments have failed to achieve adequate metabolic
control. For additional information, please follow this
https://www.globenewswire.com/Tracker?data=e2ZYWajWFEbMEAC92Qw2Xp1CS3UPbpYUoygGhO3FyW1Q_wjPG7dnzV5TljxchVDDoqpaiLr25-4kb5wsZIMfVPqooRfAlnr7-PIRa-DtKe0li3zwCzDJbKIzuVbKfkNmsOxawOAAFLj6dsNmgeGE6Rg20QwN54Vf1tyWoedxHWs=
link.
Juxtapid(R)/ Lojuxta(R) (lomitapide) is approved as an adjunct to a
low-fat diet and other lipid-lowering medicinal products for adults with
the rare cholesterol disorder, Homozygous Familial Hypercholesterolaemia
("HoFH") in the US, Canada, Columbia, Argentina and Japan (under the
trade name Juxtapid(R)) and in the EU, Israel and Brazil (under the
trade name Lojuxta(R)). For additional information, please follow this
https://www.globenewswire.com/Tracker?data=e2ZYWajWFEbMEAC92Qw2XpZF9xBNB_4j-FN5aKdQVihrNr47EaIvwHvClW_xUzY8Gyk3PEzh6lE3mtVFzfdJerFLOIbhTb-r9rZv8m58KRA=
link.
Amryt's lead development candidate, Filsuvez(R) (Oleogel-S10) is a
potential treatment for the cutaneous manifestations of Junctional and
Dystrophic Epidermolysis Bullosa ("EB"), a rare and distressing genetic
skin disorder affecting young children and adults for which there is
currently no approved treatment. Filsuvez(R) has been selected as the
brand name for Oleogel-S10. The product does not currently have
regulatory approval to treat EB.
Amryt's pre-clinical gene therapy platform, AP103, offers a potential
treatment for patients with Dystrophic EB, and is also potentially
relevant to other genetic disorders.
For more information on Amryt, including products, please visit
www.amrytpharma.com.
This announcement contains inside information for the purposes of
article 7 of the Market Abuse Regulation (EU) 596/2014. The person
making this notification on behalf of Amryt is Rory Nealon, CFO/COO and
Company Secretary.
Financial Advisors
Shore Capital (Edward Mansfield, Daniel Bush, John More) are NOMAD and
Joint Broker to Amryt in the UK. Stifel (Ben Maddison) are Joint Broker
to the company in the UK. Davy (John Frain, Daragh O'Reilly) act as
Joint Broker to the company.
Forward-Looking Statements
This press release may contain forward-looking statements containing the
words "expect", "anticipate", "intends", "plan", "estimate", "aim",
"forecast", "project" and similar expressions (or their negative)
identify certain of these forward-looking statements. The
forward-looking statements in this announcement are based on numerous
assumptions and Amryt's present and future business strategies and the
environment in which Amryt expects to operate in the future.
Forward-looking statements involve inherent known and unknown risks,
uncertainties and contingencies because they relate to events and depend
on circumstances that may or may not occur in the future and may cause
the actual results, performance or achievements to be materially
different from those expressed or implied by such forward-looking
statements. These statements are not guarantees of future performance or
the ability to identify and consummate investments. Many of these risks
and uncertainties relate to factors that are beyond each of Amryt's
ability to control or estimate precisely, such as future market
conditions, the course of the COVID-19 pandemic, currency fluctuations,
the behaviour of other market participants, the outcome of clinical
trials, the actions of regulators and other factors such as Amryt's
ability to obtain financing, changes in the political, social and
regulatory framework in which Amryt operates or in economic,
technological or consumer trends or conditions. Past performance should
not be taken as an indication or guarantee of future results, and no
representation or warranty, express or implied, is made regarding future
performance. No person is under any obligation to update or keep current
the information contained in this announcement or to provide the
recipient of it with access to any additional relevant information that
may arise in connection with it. Such forward-looking statements reflect
the Company's current beliefs and assumptions and are based on
information currently available to management.
Contacts
Joe Wiley, CEO / Rory Nealon, CFO/COO, +353 (1) 518 0200,
https://www.globenewswire.com/Tracker?data=Y2ZYBxdBKEJhF41HUcO4C7SdKpcxXtu7kSuPhgJmpRcR2zXzeyFrnsofKSiqLkRNYazO0xsBXD97zO1qu57h7HpjnCLCHqNz2pLC4WOXoWQ=
ir@amrytpharma.com
Edward Mansfield, Shore Capital, NOMAD, +44 (0) 207 468 7906,
edward.mansfield@shorecap.co.uk
Tim McCarthy, LifeSci Advisors, LLC, +1 (212) 915 2564,
tim@lifesciadvisors.com
Amber Fennell, Consilium Strategic Communications, +44 (0) 203 709 5700,
https://www.globenewswire.com/Tracker?data=IEeOje_BbyggFJCrjiyLfzAOc5RBe0u1gStMi5Ohxp13nrG29VBKhlFRk0W62zj0kS6Yp8lKKVyrwmTsCWXCfOhuLPg4QEc9wspbNUqO1i_AOsMqridP_N2Mhoys5r5E
fennell@consilium-comms.com
(END) Dow Jones Newswires
March 08, 2021 13:00 ET (18:00 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Amryt Pharma (LSE:AMYT)
Gráfico Histórico do Ativo
De Fev 2025 até Mar 2025
Amryt Pharma (LSE:AMYT)
Gráfico Histórico do Ativo
De Mar 2024 até Mar 2025
